AT-13387
CAS: 912999-49-6
Ref. 3D-FA145338
5mg | 172,00 € | ||
10mg | 248,00 € | ||
25mg | 436,00 € | ||
50mg | 582,00 € | ||
100mg | 863,00 € |
Informação sobre produto
- Onalespib
- (2,4-Dihydroxy-5-isopropylphenyl)[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone
- (2,4-Dihydroxy-5-propan-2-ylphenyl)-[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone
- 1H-Isoindole, 2-[2,4-dihydroxy-5-(1-methylethyl)benzoyl]-2,3-dihydro-5-[(4-methyl-1-piperazinyl)methyl]-
- At 13387X
- At-13387
- Ati 3387
- Methanone, [1,3-dihydro-5-[(4-methyl-1-piperazinyl)methyl]-2H-isoindol-2-yl][2,4-dihydroxy-5-(1-methylethyl)phenyl]-
- [1,3-Dihydro-5-[(4-methyl-1-piperazinyl)methyl]-2H-isoindol-2-yl][2,4-dihydroxy-5-(1-methylethyl)phenyl]methanone
AT-13387 is a potent and selective HSP90 inhibitor that binds to the ATP binding site of HSP90 with high affinity. It has been shown to inhibit the proliferation of HL-60 cells in vitro. AT-13387 induces apoptosis in cancer cells by inhibiting the signaling pathways involved in regulating cell growth, including the activation of toll-like receptor 4 (TLR4). The efficacy of AT-13387 was evaluated in vivo using an animal model with bowel disease, which showed significant inhibition of tumor growth. AT-13387 also inhibits TLR4 signaling, suggesting that it may be useful for treating bowel disease. AT-13387 is being developed as a potential therapy for cancer and other diseases associated with TLR4 activation.
Propriedades químicas
Consulta técnica sobre: 3D-FA145338 AT-13387
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.